Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores

Jacob Rozmus, John E. Levine, Kirk R. Schultz

Research output: Contribution to journalArticlepeer-review

Abstract

Prevention of acute and chronic graft-versus-host disease (aGvHD and cGvHD) is an important objective of allogeneic hematopoietic cell transplantation (HCT). While there is has been significant progress in preventative approaches in the peritransplant period to minimize development of GvHD, no preventative approach has completely eliminated development of either aGvHD or cGvHD. Recently, posttransplant immune biomarker profiling early post-HCT by the Mount Sinai Acute GvHD International Consortium group has resulted in a validated risk assignment algorithm and development of preemptive approaches to decrease aGvHD and mortality in high-risk patients. cGvHD risk assignment algorithms have been developed based on measurements at day 100 and may be used for future preemptive intervention trials to minimize cGvHD. This article discusses the current state of the art in aGvHD and cGvHD preemptive algorithms and therapeutic interventions and what is needed to move these into validated approaches.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalHematology. American Society of Hematology. Education Program
Volume2023
Issue number1
DOIs
StatePublished - 8 Dec 2023

Cite this